Aduro Biotech Announces New Corporate Offices and Laboratory Space

BERKELEY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the opening of a new corporate office and laboratory facility, which will serve as the company’s new global headquarters for its U.S. and European operations.

“Over the course of the last two years, we have grown significantly, both in the number of programs and in our employee base, and we have outgrown our former location,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We are extremely pleased to remain in Berkeley, maintaining our roots and our key connections with both the University of California, Berkeley and this extraordinary community. Our new facility also provides room to grow as we continue to advance our three technology platforms focused on the development of immunotherapies that transform the treatment of challenging diseases.”

Aduro recently moved into the 110,853-square foot building at 740 Heinz Avenue, in the 17-building Aquatic Park Center research and development campus in West Berkeley.

The company will be hosting an open house on Thursday, September 1, 2016 from 4:00 p.m. to 6:00 p.m. PT at 740 Heinz Avenue in Berkeley, CA. Congresswoman Barbara Lee, Assemblymember Tony Thurmond, Councilmember Darryl Moore, Mayor Tom Bates and the Honorable Nancy Skinner will be in attendance. Guided tours of the facility will be available every 20 minutes. Members of the media interested in attending the event may RSVP to

“Technology and innovation are helping to drive our economy forward. As these new technologies are applied to healthcare, they are helping people live longer, healthier lives. I am pleased to know Aduro Biotech, a cutting-edge leader in immunotherapy, will remain in Berkeley and continue the East Bay’s tradition of world-leading innovation in healthcare and biotech,” said Congresswoman Barbara Lee.

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology platforms, future growth, plans and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “could,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended June 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Alexandra Santos Senior Director, Corporate Affairs 510 809 9231 Media Contact: Angela Bitting 925 202 6211

Source:Aduro Biotech, Inc.